A Phase 1 interventional study of Savolitinib and Digoxin in Healthy Male Subjects, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-13.
Sponsored by AstraZeneca · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess the effects of savolitinib on the pharmacokinetics (PK) of substrates of human transporters digoxin (P-gp), rosuvastatin (OATP1B1/3), metformin (OCT2, MATE1/2K), and furosemide (OAT1/3) in healthy male subjects, performed at a single clinical unit.
This study will be performed at a single clinical unit.
Subjects will be admitted to the clinical unit on Day -1 of Period 1 and Period 2. Subjects will have a washout period of 14 days between Period 1 and Period 2.
Period 1: Subjects will recieve a single dose of a drug cocktail of 4 medications (digoxin Dose B, furosemide Dose C, metformin hydrochloride Dose D, and rosuvastatin Dose E).
Period 2: Participants will receive savolitinib (Dose A) in combination with the drug cocktail of 4 medications as received in Period 1.
The study will consist of 4 visits:
Visit 1 (Enrollment): Following full written informed consent, subjects will be screened for eligibility.
Visit 2 (Period 1: Treatment and Sample Collection Period): Each subject will be admitted to the clinical unit on Day -1 of Period 1, single dose of drug cocktail is administered on Day 1, and remain in clinical unit until Day 5 assessments. A washout period of 14 days is followed.
Visit 3 (Period 2: Treatment and Sample Collection Period): Each subject will be admitted to the clinical unit on Day -1 of Period 2, single dose of savolitinib and drug cocktail is administered, and remain in clinical unit until Day 5 assessments.
Visit 4 (Follow-up): Subjects will attend the clinical unit for a final Follow-up Visit 5 to 7 days post Day 5 in Period 2.
Each subject will be involved in the study for 9 weeks including screening to final follow up.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive two different interventions in two periods (Periods 1 and 2). In Period 1, the subjects will receive a single-dose of Drug cocktail components (digoxin Dose B, furosemide Dose C, metformin hydrochloride Dose D, and rosuvastatin Dose E). During Period 2, the subjects will receive savolitinib dose A in combination with the Drug cocktail components.
Drug: Savolitinib · Drug: Digoxin · Drug: Metformin Hydrochloride · Drug: Rosuvastatin · Drug: Furosemide
The subjects will receive single dose of oral film-coated tablet of Savolitinib A dose on Day 1 of Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
The subjects will receive single dose of oral uncoated tablet of Digoxin Dose B on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
The subjects will receive single dose of oral film-coated tablet of Metformin Hydrochloride Dose D on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
The subjects will receive single dose of oral film-coated tablet of Rosuvastatin Dose E on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
The subjects will receive single dose of oral solution of Furosemide Dose C on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Plasma Area Under Concentration-time Curve from zero to infinity (AUCinf) of the drug cocktail components
To evaluate AUCinf of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2)
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Plasma Area under the concentration-curve from zero to the last quantifiable concentration (AUClast) of the drug cocktail components
To evaluate AUClast of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2)
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Plasma partial area under the concentration-time curve from time 0 to time t post-dose (AUC(0-t)) of the drug cocktail components
To evaluate (AUC(0-t)) of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2).
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Maximum observed plasma drug concentration (Cmax) of drug cocktail components
To evaluate Cmax of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2).
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
The ratio of plasma AUCinf (R AUCinf) of the drug cocktail components in the presence and absence of savolitinib
To evaluate AUCinf ratio of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2).
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
The ratio of plasma AUC(0-t) (R AUC(0-t)) of the drug cocktail components in the presence and absence of savolitinib
To evaluate AUC(0-t) ratio of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2).
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
The ratio of plasma Cmax (R Cmax) of drug cocktail components in the presence and absence of savolitinib
To evaluate Cmax ratio of drug cocktail components when administered alone (period 1) and in combination with savolitinib (period 2).
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Number of participants with adverse events
To assess safety and tolerability of savolitinib following oral dosing.
Time frame: Day 1 in Periods 1 (Week 1) and 2 (Week 4) to Day 7 (follow-up after last Pharmacokinetic (PK) sample)
Area under plasma concentration-time curve from zero to infinity (AUCinf) of savolitinib and its metabolites (M2 and M3)
To assess AUCinf of savolitinib and its metabolites (M2 and M3).
Time frame: Day 1 and Day 2 in Period 2 (Week 4)
Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUCinflast) of savolitinib and its metabolites (M2 and M3)
To assess AUClast of savolitinib and its metabolites (M2 and M3)
Time frame: Day 1 and Day 2 in Period 2 (Week 4)
Partial area under the concentration-time curve from time 0 to time t post-dose (AUC(0-t)) of savolitinib and its metabolites (M2 and M3)
To assess AUC(0-t) of savolitinib and its metabolites (M2 and M3).
Time frame: Day 1 and Day 2 in Period 2 (Week 4)
Maximum observed plasma (peak) drug concentration (Cmax) of savolitinib and its metabolites (M2 and M3) of savolitinib and its metabolites (M2 and M3)
To assess Cmax of savolitinib and its metabolites (M2 and M3).
Time frame: Day 1 and Day 2 in Period 2 (Week 4)
Observed lowest concentration before the next dose is administered (Ctrough) of savolitinib and its metabolites (M2 and M3)
To assess Ctrough of savolitinib and its metabolites (M2 and M3).
Time frame: Day 1 and Day 2 in Period 2 (Week 4)
Terminal elimination half-life (t½λz) of savolitinib and its metabolites (M2 and M3)
To assess t½λz of savolitinib and its metabolites (M2 and M3).
Time frame: Day 1 and Day 2 in Period 2 (Week 4)
Time to reach maximum observed concentration (tmax) of savolitinib and its metabolites (M2 and M3)
To assess tmax of savolitinib and its metabolites (M2 and M3).
Time frame: Day 1 and Day 2 in Period 2 (Week 4)
Apparent volume of distribution based on the terminal phase (Vz/F) of savolitinib and its metabolites (M2 and M3)
To assess Vz/F of savolitinib and its metabolites (M2 and M3).
Time frame: Day 1 and Day 2 in Period 2 (Week 4)
Apparent total body clearance (CL/F) of savolitinib and its metabolites (M2 and M3)
To assess CL/F of savolitinib and its metabolites (M2 and M3).
Time frame: Day 1 and Day 2 in Period 2 (Week 4)
Maximum observed plasma (peak) drug concentration (Cmax) of cocktail parent components
To assess the Cmax of the drug cocktail parent components.
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Time to reach maximum observed plasma concentration (Tmax) of the cocktail parent components
To assess the PK parameter tmax of the drug cocktail parent components
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Plasma terminal elimination half-life (t½λz) of cocktail parent components
To assess the PK parameter t½λz of the drug cocktail parent components.
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Plasma terminal rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (λz) of cocktail parent components
To assess the PK parameter λz of the drug cocktail parent components.
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Plasma Apparent total body clearance (CL/F) of cocktail parent components
To assess the PK parameter CL/F of the drug cocktail parent components.
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Plasma Apparent volume of distribution based on the terminal phase (Vz/F) of cocktail parent components
To assess the PK parameter Vz/F of the drug cocktail parent components.
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Renal clearance (CLR) of cocktail parent components
To assess the urine PK parameter CLR of the drug cocktail parent components.
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Cumulative amount of unchanged drug excreted into urine (Ae) of cocktail parent components
To assess the urine PK parameter Ae of the drug cocktail parent components.
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Cumulative amount of unchanged drug excreted into the urine from time 0 to time t (Ae(0-t)) of cocktail parent components
To assess Ae(0-t) of the drug cocktail parent components
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Percentage of dose excreted unchanged in urine from time 0 to t (fe(0-t)) of cocktail parent components
To assess fe(0-t) of the drug cocktail parent components.
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Cumulative amount of unchanged drug excreted into urine (CumAe) of the cocktail parent components
To assess CumAe of the drug cocktail parent components
Time frame: Day 1 to Day 5 in Periods 1 (Week 1) and 2 (Week 4)
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Ran from Apr 2023 to primary completion in Jun 2023, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Savolitinib · Digoxin · Metformin · Rosuvastatin · Furosemide